ストックスクリーナーアプリを入手
0.99
43.27%
0.299
アフターアワーズ：
1.02
0.03
+3.03%
前日終値:
$0.691
開ける：
$0.7228
24時間の取引高:
10.90M
Relative Volume:
5.92
時価総額：
$2.87M
収益：
-
当期純損益:
$-11.38M
株価収益率:
-0.0382
EPS:
-25.91
ネットキャッシュフロー:
$-12.72M
1週間 パフォーマンス:
+41.03%
1か月 パフォーマンス:
-69.06%
6か月 パフォーマンス:
+146.70%
1年 パフォーマンス:
-26.67%
1日の値動き範囲:
$0.7228
$1.10
1週間の範囲:
$0.6574
$1.10
52週間の値動き範囲:
$0.2654
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
名前
Windtree Therapeutics Inc
セクター
電話
(215) 488-9300
住所
2600 KELLY ROAD, WARRINGTON, PA
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-26 | 開始されました | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc (WINT) 最新ニュース
Windtree Therapeutics secures Japan patent for heart drug By Investing.com - Investing.com UK
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewswire
A significant driver of top-line growth: Windtree Therapeutics Inc (WINT) - SETE News
Windtree Therapeutics Inc (WINT) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Windtree Therapeutics Inc (WINT) - Knox Daily
Was Windtree Therapeutics Inc (WINT)’s session last reading good? - US Post News
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones - Research Tree
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MSN
Ladenburg Thalmann slashes price target on Windtree Therapeutics Inc [WINT] – find out why. - The DBT News
Windtree Therapeutics CEO buys $4.9k in company stock - Investing.com India
Windtree Therapeutics advances Phase 2b cardiogenic shock study By Investing.com - Investing.com Australia
Windtree Therapeutics CEO buys $4.9k in company stock By Investing.com - Investing.com Australia
WINT’s Stock Journey: What Investors Need to Know About Windtree Therapeutics Inc’s Performance - The InvestChronicle
Windtree Therapeutics advances Phase 2b cardiogenic shock study - Investing.com India
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - GlobeNewswire
Taking on analysts’ expectations and winning: Windtree Therapeutics Inc (WINT) - SETE News
Ratios Reveal: Breaking Down Windtree Therapeutics Inc (WINT)’s Financial Health - The Dwinnex
Examining Windtree Therapeutics Inc (WINT) stock is warranted - US Post News
Windtree Therapeutics Announces Recent Stock Transactions By Investing.com - Investing.com South Africa
Windtree Therapeutics Announces Recent Stock Transactions - Investing.com
WINT stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Canada
Windtree Therapeutics Inc (WINT) is a good investment, but the stock may be undervalued - US Post News
Windtree Therapeutics names new CFO By Investing.com - Investing.com Australia
Windtree Therapeutics names new CFO - Investing.com
Windtree Therapeutics Appoints New Senior VP and CFO - TipRanks
Financial Fitness Check: Examining Windtree Therapeutics Inc (WINT)’s Key Ratios - The Dwinnex
Windtree Therapeutics Announces Positive Results in Heart Failure Study - MyChesCo
Windtree Therapeutics Updates Investor Presentation Materials - TipRanks
Windtree Therapeutics Inc Inc. (WINT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Windtree reports positive heart failure drug study results - Investing.com
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewswire
Windtree Therapeutics Announces Promising Results for Heart Failure Drug - MSN
Windtree Therapeutics Announces Key Investor Day for Groundbreaking Heart Treatment - MSN
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - GlobeNewswire
Financial Metrics Unveiled: Windtree Therapeutics Inc (WINT)’s Key Ratios in the Spotlight - The Dwinnex
Windtree reports positive Phase 2b results for heart failure drug By Investing.com - Investing.com Australia
Windtree reports positive Phase 2b results for heart failure drug - Investing.com India
Windtree Therapeutics Inc (WINT) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Declines By 65.9% - Defense World
WINT’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure - AOL
Windtree stock slides amid Phase 2b data for istaroxime for cardiogenic shock - MSN
Windtree Announces Positive Topline Results from Its Phase - GlobeNewswire
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock - StockTitan
Windtree Therapeutics secures stockholder approvals in key proposals - Investing.com India
Windtree Therapeutics Inc (WINT) 財務データ
収益
当期純利益
現金流量
EPS
8.06%
0.77%
大文字化:
|
ボリューム (24 時間):